Racial, ethnic disparities explored in subjective cognitive decline
Jul 08, 2021
More Black and Hispanic adults than white adults report subjective cognitive decline at age 45 to 54 years.
Yoga, meditation improve brain fitness: study
By
Lois A. Bowers
May 11, 2016
Yoga and meditation can offer a simple, safe and low-cost solution for improving brain fitness, according to new research. Combined, they were found to be even more effective than what many consider to...
Lumosity to pay $2 million to settle deceptive advertising charges
By
Lois A. Bowers
Jan 07, 2016
Lumosity has agreed to pay $2 million to settle Federal Trade Commission charges that it deceived consumers with unfounded claims that its “brain games” can reduce or delay cognitive impairment...
Antipsychotic prescribing increases in assisted living during pandemic: study
By
Kimberly Bonvissuto
Apr 11, 2022
The prescribing of antipsychotic medications in assisted living communities and nursing homes has increased by 1.5% since the beginning of the COVID-19 pandemic, according to a recent study.
Higher habitual coffee intake may slow cognitive decline
Nov 30, 2021
Higher baseline coffee consumption also was linked to slower Aβ-amyloid accumulation during a 126-month study period, as shown on brain MRI scans.
Fund Alzheimer’s research, Senate committee told
By
Lois A. Bowers
Apr 06, 2016
Witnesses testifying before the Senate Special Committee on Aging, and committee members themselves, called for more funding for Alzheimer’s research at an April 6 hearing.
McKnight’s Senior Living Online Expo set for June 13
By
Lois A. Bowers
May 14, 2018
Registration is now open for the second annual McKnight’s Senior Living Online Expo, where attendees can earn up to three continuing education credits and interact with several companies serving...
Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.
3 FDA advisory panel members resign in wake of controversial approval of new Alzheimer’s drug
By
Kimberly Bonvissuto
Jun 11, 2021
Three members of a Food & Drug Administration advisory panel resigned this week over the agency’s controversial decision on Monday to approve a novel therapy for Alzheimer’s disease.
Most with Alzheimer’s disease, mild cognitive impairment would have been excluded from aducanumab...
Sep 16, 2021
Overall, 92.2, 91, and 85.5% of Medicare beneficiaries with Alzheimer’s disease-related disorders, Alzheimer’s disease, and mild cognitive impairment met at least one of the exclusion criteria.